Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Eye drop showdown: which artificial tear works best for dry eyes?

NCT ID NCT07451184

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study compares two lubricating eye drops—Systane PRO PF and Thealoz Duo—to see which one better relieves dry eye symptoms. About 100 adults with dry eye will use each drop for 4 weeks, one twice a day and the other four times a day. The goal is to find out if they work equally well or if one provides superior comfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

36 people

The number who actually took part.

Started

Feb 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Are at least 18 years of age and have full legal capacity to volunteer; 2. Have understood and signed an institutional review board (IRB)/ independent ethics committee (IEC) approved informed consent form; 3. Are willing and able to attend all study visits as required per protocol; 4. Are willing to discontinue use of all habitual artificial tear supplements and use only the study drops as directed for the entire study duration; 5. Have dry eye symptomatology as per Tear Film \& Ocular Surface Society Dry Eye WorkShop (TFOS DEWS) II definition: * Have an Ocular Surface Disease Index (OSDI) score ≥13; 6. Have an absence of active\* anterior segment disease; 7. Have not worn contact lenses for the previous 14 days before screening, and are willing to not wear contact lenses for the duration of the study; 8. Are correctable to a visual acuity of +0.20 LogMAR or better (in at least one eye) with refraction results. Exclusion Criteria: 1. Have taken part in an interventional clinical study within the previous 14 days before screening; 2. Are participating in any concurrent ocular or interventional clinical trial; 3. Have any active\* ocular inflammation, infection, or are using ocular topical treatment (other than dry eye drops); 4. Started any systemic medication known to cause dry eye (e.g., anti-histamine, antidepressants, benzodiazepines, etc.) within 30 days before screening. Stable dosing for \>30 days before screening is allowed, but changes (including commencing new) of dosing of such medication within the study period would lead to early exit from the study; 5. Had any ocular injury or surgery within the 1 year prior to screening, nor have ocular surgery planned/ anticipated; 6. Have biomicroscopy signs of grade 3 or more (Efron scale); 7. Have known sensitivity to the diagnostic pharmaceuticals or to any ingredients in the study products; 8. Are pregnant, lactating or planning a pregnancy at the time of enrolment; 9. Are a member of the Centre for Ocular Research \& Education directly involved in this study (on the delegation log); 10. Are an employee of Alcon.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Ocular Research & Education (CORE)

    Waterloo, Ontario, N2L 3G1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.